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521Lipoprotein(a) [Lp(a)] consists of a cholesterol-rich low-
density lipoprotein (LDL) moiety that is covalently linked to
apolipoprotein(a). Evidence from genetic studies indicates
that Lp(a) may play a causal role in the development of
atherosclerosis (1). In the ﬁrst of 2 large Mendelian
randomization studies, genetic polymorphisms in the LPA
gene were shown to inﬂuence Lp(a) levels and increase the
risk of myocardial infarction (MI) in Danish subjects. In
particular, a doubling of Lp(a) levels throughout life was
associated with a 22% increase in the risk of MI (2,3). In
a case-control study in 4 European countries, 2 common
variants in the LPA gene were found to be strongly associ-
ated with Lp(a) levels, and individuals with these variants
had more than a 50% increased risk of heart disease (2,3).
Further, genetically determined Lp(a) levels, as determined
by the LPA genotype, are associated with aortic valve
calciﬁcation and incident clinical aortic stenosis (4).
Although Lp(a) may prove to be a causal risk factor for
the development of ischemic heart disease, its clinical utility
as a prognostic biomarker in secondary prevention remains
a separate issue that is incompletely deﬁned. Recently,
a large pooled analysis in primary prevention populations
conﬁrmed that Lp(a) was an independent risk factor for
coronary heart disease (CHD) death, nonfatal MI, and
stroke, although the strength of the relationship appeared
to be modest when Lp(a) was modeled as a continuous
variable (5). In quantile analysis, the relationship appeared
curvilinear (5), with signiﬁcantly greater risk observed for
those patients with Lp(a) levels in the highest quartile,
consistent with prior reports from individual studies (6–8).
As well, there was a trend toward a stronger association
between Lp(a) and cardiovascular (CV) events for patients
with higher non–high-density lipoprotein cholesterol levels
(5), a ﬁnding that has been observed with LDL cholesterol
in other analyses (7,9).
Although data in secondary prevention populations are
limited, some professional societies have now endorsed
routine 1-time screening for Lp(a) in individuals at inter-
mediate or high risk of CV events, including selected
patients with established coronary artery disease (CAD)
(10,11). Moreover, it has been proposed that an Lp(a)
level <50 mg/dl (w80th percentile in the general pop-
ulation) should be targeted with therapies that lower Lp(a),
such as niacin (10).as a consultant to Amgen, Eli Lilly, Merck, Roche, and sanoﬁ-aventis; has received
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accepted September 24, 2013.Given that data regarding the
prognostic value of Lp(a) in
secondary prevention are sparse
and new lipid-modifying thera-
pies that reduce Lp(a) are in
development (12–15), we assessed
the independent prognostic utility
of Lp(a) and evaluated proposed
screening cut points in 3 large
clinical trial populations of
patientswith either stableCADor
after an acute coronary syndrome
(ACS). We further assessed the
prognostic utility of Lp(a) by
combining the new data with
previously published secondary
prevention studies, and assessed
for effect modiﬁcation by LDL or
total cholesterol concentration.Methods
Study populations and design. The PEACE (Prevention
of Events with Angiotensin Converting Enzyme Inhibition)
trial (16) enrolled patients with stable CAD and preserved left
ventricular function. The CARE (Cholesterol and Recurrent
Event) trial (17) randomized patients who had experienced an
MI within the past 3 to 20 months to pravastatin 40 mg daily
versus placebo. The PROVE IT–TIMI 22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy–Thrombol-
ysis In Myocardial Infarction 22) trial (18) randomized
patients following an ACS to atorvastatin 80 mg daily versus
pravastatin 40 mg daily. Further details regarding the study
designs are provided in the Appendix.
Based on prior data for Lp(a) (5), the clinical endpoint of
interest for this analysis was major adverse cardiovascular
events (MACE) deﬁned as the composite of CV death, MI,
or stroke, where available. Of note, in the CARE trial, Lp(a)
was measured in an age-matched case-control population of
subjects who had or had not experienced fatal CHD or
recurrent MI. Endpoints were adjudicated by clinical events
committees who were blinded to treatment assignment and
to Lp(a) levels.
Blood sampling and analysis. As part of the study proto-
cols, samples of venous blood were to be collected in EDTA-
treated tubes from participating subjects in the PEACE,
PROVE IT–TIMI 22, and CARE trials. The plasma com-
ponent was frozen and shipped to a central laboratory where
samples were stored at 70C or colder. Details regarding
the assays used to measure Lp(a) concentration in each trial
are provided in the Online Appendix.
Statistical analysis. In order to evaluate its association
with clinical outcomes, Lp(a) was ﬁrst analyzed as a log-
transformed continuous variable and was subsequently
categorized into quintiles according to Lp(a) concentration.
Given the previously demonstrated curvilinear relationship
OR (95% CI)
Relative 
P Value Weight (%)
PEACE 1.01 (0.90-1.14) 0.87 39.13
CARE 1.04 (0.92-1.18) 0.53 34.45
PROVE IT-TIMI 22 1.04 (0.90-1.20) 0.59 26.42
1.03 (0.96-1.11) 0.46OVERALL
0.8 0.9 1 1.2 1.6
Odds Ratio (95% CI) for MACE
SD of log transformed Lp(a)per 1- -
Figure 1 Lp(a) and Odds of MACE
Effect estimates are per 1 SD of log-transformed lipoprotein(a) [Lp(a)]. For the
PEACE and PROVE IT–TIMI 22 trials, major adverse cardiac events (MACE) con-
sisted of cardiovascular death, myocardial infarction (MI), or stroke; for CARE,
MACE consisted of fatal coronary heart disease or MI due to its case-control
design. Results from individual studies are combined using meta-analysis.
CI ¼ conﬁdence interval; OR ¼ odds ratio.
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522with events (5), further analyses were performed to evaluate
previously proposed cut points (e.g., 50 mg/dl and 95th
percentile). Event rates were estimated using the Kaplan-
Meier method. Cox proportional hazard or logistic regres-
sion models were used to estimate the association between
Lp(a) and CV events where appropriate. Multivariable
models were created to adjust for baseline characteristics,
lipid levels, and treatments that were signiﬁcantly associ-
ated with Lp(a) concentration (see a detailed list of cova-
riates in Online Tables 1 to 6). In toto, the PEACE,
CARE, and PROVE IT–TIMI 22 trials had 80% power
to detect: a 10% increase in the odds of MACE per 1-SD of
log-transformed Lp(a); a 27% increase in MACE in the
top quintile; and a 51% increase in MACE for those
patients with Lp(a) levels in the top 5th percentile.
To place the current ﬁndings in the context of previously
published studies, data were extracted from previously
published reports of Lp(a) in secondary prevention. Because
variable thresholds of Lp(a) were used in each study, the
relative risk or odds of MACE in the highest versus
lowest quantile of Lp(a) was employed where available
(Online Fig. 1) (19–26). For the purpose of the meta-
analysis, the odds ratio [OR] (95% conﬁdence interval
[CI]) was calculated for each study wherever possible using
logistic regression models. A meta-analysis was then con-
ducted based on random-effects models using the method
by DerSimonian and Laird (27). Between-study heteroge-
neity of risk was assessed using Cochran’s Q statistic and
the degree assessed using the I2 measure (the percentage of
total variability due to true between-study heterogeneity)
(28). The meta-analysis was then stratiﬁed by the average
study-speciﬁc baseline LDL cholesterol (or baseline total
cholesterol when LDL cholesterol was not available). For
randomized trials of lipid-lowering therapy, achieved rather
than baseline LDL cholesterol was used, because the base-
line value did not reﬂect the patients’ LDL cholesterol
during the period at risk. An LDL cholesterol threshold
of <130 mg/dl or 130 mg/dl (3.37 mMol/l) [or total
cholesterol <200 mg/dl or 200 mg/dl (5.18 mMol/l)] was
used, consistent with the National Cholesterol Education
Program Adult Treatment Panel III Guidelines (29).
Because all analyses were considered to be exploratory, all
tests were 2-sided, with a p value <0.05 considered to
be signiﬁcant. Further statistical considerations are provided
in the Online Appendix.
Results
In the current analysis, Lp(a) was measured in 6,708
patients, including 3,394 patients with stable CAD from
the PEACE trial, 785 patients with a prior MI from the
CARE trial, and 2,529 patients stabilized after a recent ACS
from the PROVE IT–TIMI 22 trial. The baseline charac-
teristics of patients in the 3 trials by Lp(a) concentration are
shown in Online Tables 1 to 3. In general, Lp(a) was not
consistently associated with traditional CV risk factors,except that patients with higher Lp(a) levels had mildly
higher levels of LDL cholesterol or apolipoprotein B, which
is consistent with the contribution of Lp(a) to these
measures.
Association of Lp(a) levels and clinical outcomes. When
modeled as a continuous variable per 1-SD increase in log-
transformed Lp(a) concentration, there was no association
between baseline Lp(a) levels and the subsequent risk of
MACE in the PEACE trial (hazard ratio [HR]: 1.03, 95%
CI: 0.93 to 1.14), the CARE trial (OR: 1.04, 95% CI: 0.92
to 1.18), or the PROVE IT–TIMI 22 trial (HR: 1.04, 95%
CI: 0.90 to 1.20). When data were meta-analyzed across the
3 trials, there remained no association between higher levels
of log-transformed Lp(a) and the risk of MACE (OR per
1-SD: 1.03, 95% CI: 0.96 to 1.11, p ¼ 0.46) (Fig. 1) or the
odds of CV death or MI (OR per 1-SD: 1.05, 95% CI:
0.97 to 1.13, p ¼ 0.25).
Exploration of threshold effect. There was no evidence of
a threshold effect for CV events when patients were cate-
gorized into quintiles of Lp(a) levels across the 3 trials.
Compared with quintile 1, patients in the top quintile of
Lp(a) concentration did not have a signiﬁcant increase in the
risk of MACE in the PEACE trial (HR: 1.06, 95% CI: 0.76
to 1.49), the CARE trial (OR: 1.08, 95% CI: 0.69 to 1.68),
or the PROVE IT–TIMI 22 trial (HR: 1.02, 95% CI: 0.65
to 1.58). When baseline data were meta-analyzed across the
3 trials, patients with levels in the top quintile were not at
higher risk for MACE (OR: 1.05, 95% CI: 0.80 to 1.34,
p ¼ 0.67) or CV death or MI (OR: 1.13, 95% CI: 0.88 to
1.44, p ¼ 0.34) versus those in the lowest quintile. Data for
individual components of MACE in each of the trials by
quintile of Lp(a) are shown in Online Tables 4 to 6.
Dichotomizing patients at an Lp(a) concentration of
50 mg/dl did not reveal a threshold of risk at this cut point.
Speciﬁcally, the HR for MACE was 1.02 (95% CI: 0.78
to 1.33) in PEACE, the OR for fatal CHD or MI was
Figure 2 Risk of MACE by Quintile of Lp(a)
The adjusted relative hazard (adjusted hazard ratio, 95% CI) of cardiovascular death, MI, or stroke by quintile of Lp(a). For the CARE trial, the adjusted relative odds (adjusted OR,
95% CI) of fatal coronary heart disease or MI are shown. Abbreviations as in Figure 1. HR ¼ hazard ratio
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5231.01 (95% CI: 0.66 to 1.57) in CARE, and the HR was
1.13 (95% CI: 0.73 to 1.76) in PROVE IT–TIMI 22.
Meta-analyzing data from all 3 trials yielded an OR of
1.08 (95% CI: 0.87 to 1.34, p ¼ 0.47) for MACE for
patients with an Lp(a) concentration above compared to
below 50 mg/dl.
Comparing patients with Lp(a) levels above the 95th
percentile with those with levels below the median, the HR
for MACE was 1.13 (95% CI: 0.67 to 1.89) in PEACE,
the OR was 0.99 (95% CI: 0.51 to 1.89) for fatal CHD
or MI in CARE, and the HR for MACE was 1.37 (95%
CI: 0.77 to 2.44) in PROVE IT–TIMI 22. When data
were meta-analyzed across the 3 trials, there remained no
signiﬁcant association between Lp(a) and CV risk for those
patients with Lp(a) levels in the top 5th percentile (OR:
1.20, 95% CI: 0.86 to 1.68, p ¼ 0.29 for MACE), although
the point estimate was nominally higher than that in models
that employed lower thresholds as cut points for Lp(a).
The results did not materially change after multivariable
adjustment (Fig. 2, Online Tables 4 to 6). There was no
evidence of effect modiﬁcation by sex, race, and the presence
of diabetes mellitus (data not shown).
Effect of statin therapy on Lp(a) concentration. In the
PROVE IT–TIMI 22 trial, in addition to values at
randomization, Lp(a) was also measured in 2,573 subjects
who were statin-naive before randomization and provided
a venous blood sample 30 days following randomization.
From baseline to 30 days, median levels of Lp(a) rose by
13% (interquartile range [IQR]: 19% to 60%, p < 0.001)
in patients randomized to pravastatin 40 mg daily and rose
by 25% (IQR: 15% to 86%, p < 0.001) in patients
randomized to atorvastatin 80 mg daily (p < 0.001 fordifference between treatment arms). There was no correla-
tion between the change in Lp(a) and the change in LDL
from baseline to day 30 for patients treated with pravas-
tatin (r ¼ 0.05, p ¼ 0.12) or atorvastatin (r ¼ 0.01,
p ¼ 0.69). As well, higher levels of Lp(a) measured at 30
days were not associated with an increased risk of CV
death, MI, or stroke (Online Table 7).
Meta-analysis of Lp(a) in secondary prevention studies.
The current results from PEACE, CARE, and PROVE
IT–TIMI 22 were then combined using meta-analysis with
those of 8 previously published studies of Lp(a) in secondary
prevention (Online Table 8), for a total of 18,978 subjects
and more than 3,000 MACE (19–26). When the 11 studies
were combined, patients with Lp(a) levels in the highest
quantile had a signiﬁcant 40% increase in the odds of
MACE (OR: 1.40, 95% CI: 1.15 to 1.71, p ¼ 0.001)
(Fig. 3). However, when assessing for heterogeneity, the
Q statistic was 34.0 (degrees of freedom: 12), p ¼ 0.001;
I2 was 65%, indicating a high degree of between-study
heterogeneity.
We then examined whether there was effect modiﬁcation
on the basis of the average LDL cholesterol concentration
(or total cholesterol concentration if LDL cholesterol was
unavailable) for each study. When results were stratiﬁed on
this basis, the association between Lp(a) levels in the
highest quantile and MACE was highly signiﬁcant in
studies with an average LDL cholesterol 130 mg/dl (OR:
1.46, 95% CI: 1.23 to 1.73, p < 0.001). By contrast, the
relationship between Lp(a) and MACE did not achieve
statistical signiﬁcance in those studies in which LDL
cholesterol was lower (OR: 1.20, 95% CI: 0.90 to 1.60, p ¼
0.21; p for interaction ¼ 0.26) (Fig. 4).
Study name
30.0)35.1-20.1(52.1S4
.0.laterennikS 72 (0.23-2.26) 0.57
CARE 1 08 (0 69 1 68) 0 75
Odds Ratio (95% CI) P Value
11.7%
2.5%
Relative WeightOdds ratio and 95% CI
. . - . .
20.0)81.61-82.1(55.4STAF
60.0)09.1-99.0(73.1SREH
17.0)35.1-57.0(70.1ECAEP
100.0<)58.3-25.1(24.2NOITARENEG
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PROVE IT-TIMI 22 1.00 (0.63-1.59) 0.99
8.0%
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0.1 0.2 0.5 1 2 5 10
Saely et al. - diabetic subjects 0.64 (0.39-1.06) 0.08
Saely et al. - non-diabetic subjects 1.47 (1.05-2.05) 0.02
AIM HIGH  - niacin arm 2.03 (1.34-3.07) 0.001
AIM HIGH  - placebo arm 2.07 (1.35-3.16) 0.001
1.40 (1.15-1.71) 0.001OVERALL
H t it Q 34 0 P 0 001 I2 65%
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Figure 3 Meta-Analysis of Published Studies of Lp(a) in Secondary Prevention
The odds of MACE for those subjects with the highest levels of Lp(a) when the current ﬁndings from PEACE, CARE, and PROVE IT–TIMI 22 were combined with 8 previously
published studies of Lp(a) in secondary prevention. Marked heterogeneity existed across studies when the eight other studies were included (p ¼ 0.001). For Saely et al. and
AIM HIGH studies, data only available in subgroups as noted in the ﬁgure. FATS ¼ Familial Atherosclerosis Treatment Study; HERS ¼ The Heart and Estrogen/progestin
Replacement Study; GENERATION ¼ Global Evaluation of New Events and Restenosis after Stent Implantation; other abbreviations as in Figure 1.
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524Stratiﬁcation on the basis of LDL cholesterol concen-
tration resolved between-study heterogeneity for those
studies with a higher average LDL cholesterol (Q df5 ¼ 5.5,
p ¼ 0.36; I2 ¼ 9%) (Fig. 4). By contrast, between-study
heterogeneity remained high among those studies with
lower LDL cholesterol concentration (Q df8 ¼ 22.7,Cohorts with average LDL<130mg/dl (or TC <240mg/dl if LDL unavailable) [n
Odds Ratio (95% CI) P ValueSubgroupStudy Name
95.0)64.1-18.0(90.1S4
88.0)90.2-35.0(50.1ERAC
24.0)1.44-02.0(00.3STAF
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Overall
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13.0)73.1-73.0(27.022IMIT-TIEVORP
Atorvastatin arm
Pravastatin arm
1(70.2HGIHMIA .35-3.16) 0.001
1.20 (0.90-1.60) 0.21
10.0)48.1-80.1(14.1S4
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Figure 4 Lp(a) and Odds of MACE by Cholesterol Concentration
The odds of MACE for those subjects with the highest levels of Lp(a) were combined acr
cholesterol concentration of <130 mg/dl versus 130 mg/dl (or total cholesterol <200 m
p ¼ 0.004, I2 ¼ 65%. Heterogeneity for studies with LDL 130 mg/dl: Qdf5 ¼ 5.5; p ¼p ¼ 0.004; I2 ¼ 65%). Removing 1 study at a time revealed
that heterogeneity was eliminated when the results of AIM-
HIGH (Atherothrombosis Intervention in Metabolic
Syndrome with Low HDL/High Triglycerides: Impact
on Global Health Outcomes) were excluded (Q df6 ¼ 6.2,
p ¼ 0.40; I2 ¼ 3%). After doing so, the odds of MACE for=12,800]
Relative Weight Odds ratio and 95% CI
16.1%
9.3%
1.1%
15.0%
9.0%
9.8%
12.3%
13.9%
=6,178]
13.7%
33.6%
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23.5%
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oss 9 studies and stratiﬁed by a study-wide average low-density lipoprotein (LDL)
g/dl or 200 mg/dl). Heterogeneity for studies with LDL <130 mg/dl: Qdf8 ¼ 22.7;
0.36, I2 ¼ 9%. Abbreviations as in Figures 1 and 3.
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525patients with elevated Lp(a) levels in those studies with an
average LDL cholesterol concentration <130 mg/dl was
0.99 (95% CI: 0.82 to 1.20, p ¼ 0.95; p for interaction
between Lp(a), MACE, and LDL cholesterol ¼ 0.003).
Discussion
Although Lp(a) may be a risk factor for the development
of coronary disease, its prognostic utility as a marker of risk
in the setting of secondary prevention is not well established.
The current ﬁndings suggest that high levels of Lp(a) in
patients with established CAD may help to identify indi-
viduals at increased risk of CV events; however, there exists
marked heterogeneity in ﬁndings across studies. In particular,
the prognostic value of Lp(a) in patients whose cholesterol
is well controlled remains unclear. These ﬁndings are rele-
vant given the recent recommendations by the European
Atherosclerosis Society Consensus Panel and National Lipid
Association Biomarkers Expert Panel to consider assess-
ment of Lp(a) concentration in selected patients with an
intermediate-to-high risk of CV events, including those
with established CAD (10,11).
Although several prior epidemiologic studies have
demonstrated an association between Lp(a) levels and CV
risk, these studies have been largely restricted to primary
prevention studies (30–34). In a large pooled analysis that
combined data from 126,634 subjects across 32 prospective
studies of patients without known CAD, Lp(a) was shown
to be signiﬁcantly associated with the risk of a ﬁrst CV
event, including CV death, MI, and stroke (5). Although
the relationship was signiﬁcant, the excess risk conferred by
elevated levels of Lp(a) was relatively modest. Assuming
a log-linear association, for every 1-SD increase in Lp(a)
concentration, there was a 13% increase in the risk of CHD.
In keeping with other studies (7,35), the pooled analysis
appeared to demonstrate a threshold effect, with much of the
risk concentrated for those patients in the top quartile of
Lp(a) values (5). Similarly, a recent analysis in the Danish
general population in 8,720 subjects concluded that Lp(a)
levels 80th percentile (47 mg/dl) may be most useful for
patient risk reclassiﬁcation (36). To date, relatively few
studies have examined the prognostic utility of Lp(a) in
patients with established CAD, and they have had mixed
results (19–26,31,37). An older meta-analysis that examined
data in primary and secondary prevention populations
concluded that the prognostic utility of Lp(a) was not as
strong in secondary prevention as in population-based
studies (31).
In the 3 studies in which we measured Lp(a), only when
we examined Lp(a) levels above the 95th percentile did we
observe a signal toward increased risk (OR: 1.20 [95% CI:
0.86 to 1.68] for MACE). The observed association was
not statistically signiﬁcant, but the ﬁndings are similar to the
risk ratios seen in the primary prevention setting with very
high levels of Lp(a) (adjusted risk ratio: 1.20 to 1.30) (5). Of
note, though, all 3 studies enrolled patients on the basis ofrelatively low cholesterol levels and/or there was widespread
use of lipid-lowering therapies, leading to LDL levels <130
and/or total cholesterol levels 200 mg/dl.
Because we observed no signiﬁcant association between
Lp(a) and the risk of CV events across 3 large secondary
prevention studies, we conducted a meta-analysis in order
to place the current ﬁndings in the context of previously
published studies. The meta-analysis enabled us to examine
studies that spanned a broader range of statin use and
LDL cholesterol levels (with study mean LDL cholesterol
levels ranging from 71 to 188 mg/dl). The meta-analysis
highlighted the existence of marked heterogeneity across
studies that have examined the prognostic utility of Lp(a).
Moreover, our ﬁndings strengthen prior observations sug-
gesting that the relationship between Lp(a) and CV events
may be attenuated in patients with lower levels of LDL
cholesterol. Speciﬁcally, in both the Physicians’ Health
Study and the Women’s Health Study, the association
between Lp(a) and MACE was apparent only in the sub-
set of the study population with higher cholesterol levels
(LDL >121 to 160 mg/dl) (7,9). Similarly, in a meta-
analysis of primary prevention populations, there was a
trend toward a stronger association between Lp(a) and
CV events for patients with higher non–high-density
lipoprotein cholesterol levels (31). Similar observations
were also reported in an early study that examined the
association between Lp(a) and the odds of CAD at angi-
ography in a population of men (38). In a subsequent
study of men with known CAD and elevated apolipopro-
tein B concentration, Lp(a) levels appeared to be no lon-
ger atherogenic in individuals whose LDL cholesterol
decreased by more than 10% from baseline after starting
lipid-lowering therapy (19). As previously reported for 1 of
the trials within our meta-analysis, the 4S trial (Scandi-
navian Simvastatin Survival Study), higher levels of Lp(a)
were associated with an increased risk of death or MI, but
the relationship appeared to be largely attenuated for those
patients randomized to simvastatin when compared with
those patients randomized to placebo (21). In an angio-
graphic trial, Lp(a) was no longer a determinant of CAD
progression in patients whose LDL cholesterol concen-
tration had been effectively lowered by diet and exercise
(39). As well, there may be a lack of beneﬁt from reducing
Lp(a) in patients with familial hypercholesterolemia whose
LDL cholesterol had been effectively lowered by apheresis
or drug therapy (40). Interestingly, 2 recent trials of niacin,
which lowers Lp(a) by w30% in addition to its other
lipoprotein effects, failed to show any clinical beneﬁt in 2
populations whose baseline LDL cholesterol levels were
well controlled at 63 to 74 mg/dl (41,42).
It should be noted that the observed trend toward effect
modiﬁcation by LDL cholesterol concentration may also be
related to the direct effects of statins on Lp(a) levels and/or
the effect of statins on any mechanisms by which Lp(a)
increases risk of MACE, because the vast majority of the
subjects in studies with an LDL cholesterol <130 mg/dl
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consistent with prior observations (43), we observed that the
use of more potent statin therapy may increase Lp(a)
concentration; therefore, the relationship between Lp(a) and
MACE may be partly attenuated in this setting.
Study limitations. Limitations for the current study
include the fact that it was designed post hoc, and sensitivity
analyses to explore cut points can only be considered
exploratory in nature. Because apolipoprotein(a) is extremely
heterogeneous in size and in content of epitopes that are
recognized by antibodies, harmonization of Lp(a) levels as
assessed by different assays cannot be readily achieved (44).
Although each of the trials in our analysis used different
assays to quantify Lp(a) concentration, consistent results
were observed across each of the 3 studies included in the
primary analysis. Lp(a) isoform number or single nucleotide
polymorphisms that predict high Lp(a) levels were not
measured (3). Because small apolipoprotein(a) isoforms with
high Lp(a) levels have been shown to be more atherogenic, it
is possible that these measures of Lp(a) may provide more
incremental information for risk stratiﬁcation. Although
there was no statistically signiﬁcant association between CV
events and Lp(a) levels in the 3 study populations that we
analyzed, if the risk was limited to those in the top 5th
percentile of Lp(a) levels, we had limited power to detect
such an association. For the meta-analysis, we did not have
access to subject-level data, precluding the ability to examine
heterogeneity by stratifying subjects on the basis of several
factors simultaneously. As is inherent to the process, there
are challenges when data are combined from different
studies that enrolled different patients and used different
laboratory assays and clinical deﬁnitions. Further variability
can stem from different approaches to combining data and
examining non–pre-deﬁned subgroups. Additional data
from very large studies, ideally with broad ranges of
cholesterol levels in patients taking and not taking a statin,
would add clarity.
Conclusions
Although the current study demonstrates that patients with
established CAD who have a high level of Lp(a) are at an
increased risk of subsequent MACE, the marked hetero-
geneity between studies raises questions regarding the value
of Lp(a) as a clinically useful biomarker for risk assessment,
particularly among patients with well-controlled LDL
cholesterol. Moreover, although Lp(a) may directly contribute
to CHD, there is currently insufﬁcient evidence to suggest
that Lp(a) levels above a discrete cut point should be used to
guide therapy or that treatment will translate into improved
clinical outcomes (41,42). Trials are now ongoing with novel
therapies that reduce Lp(a), such as the novel cholesteryl
ester transfer protein inhibitors anacetrapib (12), mipo-
mersen (45), and proprotein convertase subtilisin/kexin type
9 inhibitors (13,15), although such therapies inﬂuence other
lipid components in tandem. Recently, a speciﬁc antisenseoligonucleotide directed toward apolipoprotein(a) was
shown to lower apolipoprotein(a) and Lp(a) levels in
transgenic mice, and a phase I trial is underway (46). If
a strategy of Lp(a) reduction should ultimately prove to be
successful, it will be of interest to determine whether beneﬁt
is observed regardless of baseline Lp(a) concentration or
speciﬁc reduction in Lp(a).Acknowledgment
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